You are Currently Viewing the 2020 Medicare Plans.
Click here If you Would Like to See
The New 2022 Medicare Part-D Plans in Rhode Island.
2020 Medicare Part-D Plans in Rhode Island
There are 25 Medicare Part-D Plans available in Rhode Island from 9 different health insurance providers. You can choose from 5 prescription drug plans offering additional gap coverage. The plan with the lowest monthly premium is $13.20 and the highest monthly premium is $128.00. The highest rated PDP available in Rhode Island County received a 5 overall star rating from the CMS and the lowest rated plan is 3 stars.
(Click the Plan Name for More Details)
(⇅ Click the Header to Sort)
Return 2020 Medicare Part D Plans
Enhanced Alternative plans may offer additional gap coverage which is calculated as the percentage of generic formulary products with coverage above standard "generic" coverage gap cost-sharing benefit and/or the percentage of brand formulary products covered in addition to the coverage gap discount for applicable drugs.GAP
In 2020 once you and your plan provider have spent $4020 on covered drugs. (combined amount plus your deductible) You will be in the coverage gap. (AKA "donut hole") Once you reach the coverage gap you will pay 25% of the plans cost for covered brand-name prescription drugs and 25% on generic drugs unless your plan offers additional coverage. You will also receive discounted prescription drugs.Full LIS
Plans that offer Full Low Income Subsidy (also called Extra Help). The amount of Extra Help a beneficiary receives depends on their income and resources. Most people who qualify for Full Low Income Subsidy will pay no premiums or deductibles and pay no more than the LIS drug coverage cost limit.
Plans as of September 3, 2019.
For More Information on Ratings Please See the CMS Tech Notes.
Plans are subject to change as contracts are finalized.
Includes 2020 approved contracts/plans. Employer sponsored 800 series plans and plans under sanction are excluded. For 2020, enhanced alternative plans may offer additional cost sharing reductions in the gap on a sub-set of the formulary drugs, beyond the standard Part D benefit.